Clinical trial XL184-313
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk
| Cancers | |
|---|---|
| Organ | Multiple |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Exelixis |
| EudraCT Identifier | 2018-004567-31 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03937219 |
| Inclusion criteria | Intermediate or poor risk metastatic clear cell renal cell carcinoma in 1st line treatment. |
| Last update |